Novogen Ltd. (NVGN) Starts Presentation at 2015 Marcum MicroCap Conference

Novogen is an Australian-U.S. drug-development company. The Novogen group includes U.S.-based CanTx, Inc., a joint-venture company with Yale University. Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds are designed to kill the full heterogeneity of cells within a tumor, but with particular activity against the slowly-dividing, less differentiated cancer stem (tumor-initiating) cell. The ATM compounds are designed to combine with anti-microtubule drugs to produce comprehensive and fatal destruction of the cancer cell cytoskeleton. For more information, visit the company’s website at www.novogen.com